-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Mavorixafor, a Novel CXC4 Agonist for WHIM Syndrome: Challenges in Successful Drug Development in Rare Hematologic Disorders

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
Monday, December 9, 2024, 4:30 PM-6:00 PM

Hanny Al-Samkari, MD

Division of Hematology, Massachusetts General Hospital, Cambridge, MA

Disclosures: Al-Samkari: Agios: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; argenx: Consultancy; Alnylam: Consultancy; Alpine: Consultancy; Novartis: Consultancy, Research Funding; Pharmacosmos: Consultancy; Sobi: Consultancy, Research Funding; Vaderis: Research Funding.

See more of: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>